MARKET

BCRX

BCRX

Biocryst Pharmaceuticals Inc
NASDAQ
6.70
-0.14
-2.05%
Opening 11:16 02/12 EST
OPEN
6.82
PREV CLOSE
6.84
HIGH
6.85
LOW
6.61
VOLUME
415.65K
TURNOVER
--
52 WEEK HIGH
11.31
52 WEEK LOW
6.00
MARKET CAP
1.66B
P/E (TTM)
-141.6490
1D
5D
1M
3M
1Y
5Y
1D
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After New Hereditary Angioedema Data And Conference Spotlight
Simply Wall St · 12h ago
BioCryst Pharmaceuticals To Present Nine Abstracts From Hereditary Angioedema Portfolio At 2026 AAAAI Annual Meeting
Benzinga · 1d ago
BioCryst Unveils Positive New HAE Data for ORLADEYO and Navenibart at AAAAI 2026
Reuters · 1d ago
Weekly Report: what happened at BCRX last week (0202-0206)?
Weekly Report · 3d ago
Is Biocryst Pharmaceuticals (BCRX) Attractively Priced After Extended Share Price Weakness?
Simply Wall St · 4d ago
BioCryst Uses Equity Grants To Support Rare Disease Pipeline And Talent
Simply Wall St · 5d ago
BioCryst reports inducement grants under Nasdaq listing rule
TipRanks · 02/05 12:17
BioCryst Pharmaceuticals kündigt Veröffentlichung neuer Finanzergebnisse an
Reuters · 02/05 12:03
More
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. It has also obtained an early-stage program for atopic dermatitis, STAR0310.

Webull offers BioCryst Pharmaceuticals Inc stock information, including NASDAQ: BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.